DEFA14A: Protagonist Therapeutics Sets Date for 2025 Annual Meeting, Outlines Voting Matters

Protagonist Therapeutics has scheduled its 2025 Annual Meeting of Stockholders for June 20, 2025, outlining key voting items for shareholders.

Summary

• Protagonist Therapeutics will hold its Annual Meeting of Stockholders on June 20, 2025.
• Shareholders are being asked to vote on the election of two Class III director nominees, Harold E. Selick, Ph.D. and Bryan Giraudo, to serve until the 2028 Annual Meeting.
• A non-binding, advisory vote will be held to approve the compensation of the company's named executive officers.
• Shareholders will also vote to ratify the selection of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors is not aware of any other matters to be presented at the meeting.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, indicating a neutral sentiment. It outlines routine corporate governance matters.

Positives

• Shareholders have multiple options for voting, including online, virtual meeting participation, and by mail.
• The company provides clear instructions and deadlines for accessing proxy materials and voting.

Future Outlook

The Board of Directors anticipates addressing routine company matters at the 2025 Annual Meeting of Stockholders.

Industry Context

This is a standard proxy statement related to an annual meeting, a routine part of corporate governance for publicly traded companies.

Stakeholder Impact

• Shareholders are asked to vote on key matters affecting the company's governance and executive compensation.
• The outcome of the votes will influence the composition of the Board of Directors and the selection of the company's auditor.

Next Steps

• Shareholders should review the proxy materials and vote on the proposals.
• The company will hold its Annual Meeting on June 20, 2025.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Voting, Directors, Executive Compensation, Ernst & Young, Protagonist Therapeutics